StockNews.com Begins Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR)

StockNews.com started coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) in a research report report published on Thursday. The brokerage issued a sell rating on the biotechnology company’s stock.

Eiger BioPharmaceuticals Stock Performance

EIGR stock opened at $1.73 on Thursday. The stock has a market capitalization of $2.55 million, a P/E ratio of -0.03 and a beta of 1.83. Eiger BioPharmaceuticals has a one year low of $1.10 and a one year high of $43.35. The company has a 50 day moving average price of $4.77 and a two-hundred day moving average price of $6.98.

Eiger BioPharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.